Navigation Links
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Date:2/19/2008

Annual Nexavar Net Sales Increased 125% to $372 million in 2007; Fourth

Quarter Sales up 96% over same period last year

EMERYVILLE, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, for the fourth quarter of 2007 compared to a net loss of $20.7 million, or $0.47 per share, in the same period in the prior year. For the twelve months ended December 31, 2007, Onyx recorded a net loss of $34.2 million, or $0.67 per share, compared with a net loss of $92.7 million, or $2.20 per share, for the same period in 2006.

Nexavar net sales were $124.9 million for the quarter ended December 31, 2007, which represents a 96% increase over the $63.7 million reported in the same period in 2006 and a 19% increase over the $104.6 million reported in the quarter ended September 30, 2007. Nexavar net sales were $371.7 million in 2007, a 125% increase over the $165.0 million reported in 2006. Onyx, with its collaborator, Bayer HealthCare Pharmaceuticals Inc., or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of advanced kidney cancer and liver cancer in the U.S., European Union, and other territories internationally. In accordance with Onyx's collaboration agreement with Bayer, Bayer recognizes all revenue from the sale of Nexavar.

"We are pleased with Nexavar's continued commercial growth, generating worldwide net sales of $124.9 million for the fourth quarter and $371.7 million for 2007," said Hollings C. Renton, president, chief executive officer, and chairman
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
2. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
3. NUCRYST Pharmaceuticals announces year-end results
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
8. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
9. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
10. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
11. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 ... of the HIMSS EMR Adoption Model, the hospital ... improve patient engagement and automate processes. The leadership ... from paper-driven to electronic workflows, patient registration still ... copies of consents. With HIMSS Stage 7 attestation ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... 06, 2015 The Beryl Institute announces ... of Patient Experience Journal (PXJ), an international, open access, ... understanding and improving patient experience. The second volume of ... conversation globally, helps align the voices engaged and provides ... Published in association with The Beryl Institute, Volume 2, ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... 06, 2015 Wolters Kluwer , ... and students, announced today that in a survey of ... use of the clinical decision support resource improves the ... of 2014, UpToDate users in more than 170 countries ... month, on average. In Germany alone, 95% of all ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... Diseases than Ever ... ... childhood influenza and adolescent meningococcal,vaccinations are included in the 2008 Childhood ... Control and,Prevention (CDC), the American Academy of Pediatrics (AAP), and the,American ...
... NEW YORK, Jan. 11 The Substance Abuse ... from the National Survey on Drug Use and ... S. aged 12 to 25 have abused non-prescription,over-the- ... high at least once,in their lifetime. This announcement ...
... health care reform is too important, the stakes for, Californians ... ... changes., SACRAMENTO, Calif., Jan. 11 As the ... hammered out by Governor Arnold Schwarzenegger and Assembly,Speaker Fabian Nunez, the state,s ...
... genetic, biological causes could lead more to feel comfortable ... When people understand the genetics and biology of anorexia ... the eating disorder for their illness, says a University ... , "This is a potentially important finding because it ...
... diet and lifestyle are at root of reduced risk, , , FRIDAY, ... in your blood may reduce your risk of stroke, new research ... C in their blood had a 42 percent lower risk of ... which is in the January issue of The ...
Cached Medicine News:Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:Health Groups Release 2008 Immunization Schedules 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 4Health News:Insurance Agents Call for State Senate to Improve California's Health Care Reform Compromise 2Health News:Science Could Erase Stigma of Anorexia 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3
(Date:5/6/2015)... 2015  CTI BioPharma Corp. (NASDAQ and MTA: CTIC) ... March 31, 2015. "After reporting ... trial of pacritinib during the quarter, we have subsequently ... who are excited by the potential opportunity for pacritinib ... treatment of patients with myelofibrosis, specifically in the portion ...
(Date:5/6/2015)... May 6, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... first quarter ended March 31, 2015 and provided an ... "We continue to make progress across our targeted oncology ... Ph.D., president and CEO, Mirati. "We look forward to ... Society of Clinical Oncology meeting at the end of ...
(Date:5/6/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... with an emphasis on the treatment of primary and ... months ended March 31, 2015.  Highlights ... , Achieved quarterly product revenue of $0.44 million, an ... quarter of 2014; , Activated a prospective patient ...
Breaking Medicine Technology:CTI BioPharma Reports First Quarter 2015 Financial Results 2CTI BioPharma Reports First Quarter 2015 Financial Results 3CTI BioPharma Reports First Quarter 2015 Financial Results 4CTI BioPharma Reports First Quarter 2015 Financial Results 5CTI BioPharma Reports First Quarter 2015 Financial Results 6CTI BioPharma Reports First Quarter 2015 Financial Results 7CTI BioPharma Reports First Quarter 2015 Financial Results 8CTI BioPharma Reports First Quarter 2015 Financial Results 9Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 2Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 3Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 4Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 5Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... Cardica, Inc. (Nasdaq: CRDC ) today ... marketing. In this role, Mr. Littel will be responsible ... Cardica,s existing cardiac surgery devices and its planned MicroCutter™ ... surgery. "Chris brings experience as a successful ...
... -- ShangPharma Corporation (NYSE: SHP ) ... and biotechnology research and development outsourcing company, today ... subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired the ... River") Shanghai research facility. As ...
Cached Medicine Technology:Cardica Appoints Christopher Littel VP, Sales and Marketing 2Cardica Appoints Christopher Littel VP, Sales and Marketing 3ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2
... rod, and screw system designed to treat various ... utilizes a low profile design that incorporates anatomic ... The load sharing design of the 5.5 Titanium ... be applied when used with proper anterior column ...
BLF21A Alarm Model measures microcirculation in 1 cubic mm of tissue for real-time assessment of perfusion....
A portable, easy to use, dual-channel laser-Doppler tissue perfusion and temperature monitoring system, at a remarkably affordable price....
... featured laser doppler system for continuous ... multiple tissue sites. This latest generation ... Processing (DSP) and laser Doppler flowmetry ... to use, multi-channel monitor, setting new ...
Medicine Products: